Intravenous azithromycin-induced ototoxicity

被引：16

作者：

Bizjak, ED

Haug, MT

Schilz, RJ

Sarodia, BD

Dresing, JM

机构：

[1] Cleveland Clin Fdn, Dept Pharm S107, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA

[3] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA

来源：

PHARMACOTHERAPY | 1999年 / 19卷 / 02期

关键词：

D O I：

10.1592/phco.19.3.245.30930

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intravenous azithromycin is increasingly administered for treatment of hospitalized patients with community-acquired pneumonia. Macrolide antibiotics cause ototoxicity, which occurs most frequently when high serum concentrations are achieved. Current dosing guidelines for intravenous azithromycin can result in much higher serum concentrations than is seen with oral administration. We describe a 47-year-old woman who developed complete deafness after receiving 8 days of intravenous azithromycin.

引用

收藏

页码：245 / 248

页数：4

相关论文

共 21 条

[1] Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease [J].

Brown, BA ;

Griffith, DE ;

Girard, W ;

Levin, J ;

Wallace, RJ .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :958-964

[2] VANCOMYCIN-INDUCED AND ERYTHROMYCIN-INDUCED HEARING-LOSS IN HUMANS [J].

BRUMMETT, RE ;

FOX, KE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) :791-796

[3]

BRUMMETT RE, 1989, M ASS RES OT TAMP FL

[4] THE PHARMACOKINETICS OF AZITHROMYCIN IN HUMAN SERUM AND TISSUES [J].

FOULDS, G ;

SHEPARD, RM ;

JOHNSON, RB .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :73-82

[5] PHARMACOKINETIC AND INVIVO STUDIES WITH AZITHROMYCIN (CP-62,993), A NEW MACROLIDE WITH AN EXTENDED HALF-LIFE AND EXCELLENT TISSUE DISTRIBUTION [J].

GIRARD, AE ;

GIRARD, D ;

ENGLISH, AR ;

GOOTZ, TD ;

CIMOCHOWSKI, CR ;

FAIELLA, JA ;

HASKELL, SL ;

RETSEMA, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) :1948-1954

[6] Drug treatment of HIV-related opportunistic infections [J].

Klepser, ME ;

Klepser, TB .

DRUGS, 1997, 53 (01) :40-73

[7] HEARING-LOSS AND ERYTHROMYCIN PHARMACOKINETICS IN A PATIENT RECEIVING HEMODIALYSIS [J].

KROBOTH, PD ;

MCNEIL, MA ;

KREEGER, A ;

DOMINGUEZ, J ;

RAULT, R .

ARCHIVES OF INTERNAL MEDICINE, 1983, 143 (06) :1263-1265

[8] Safety, toleration, and pharmacokinetics of intravenous azithromycin [J].

Luke, DR ;

Foulds, G ;

Cohen, SF ;

Levy, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2577-2581

[9] Toleration of intravenous azithromycin [J].

Luke, DR ;

Foulds, G .

ANNALS OF PHARMACOTHERAPY, 1997, 31 (09) :965-969

[10] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245